5-DM-25B-NBOMe
Part of the metabolic pathway of 25B-NBOMe. See the timeline on the metabolic highway.
Overview
5-DM-25B-NBOMe, also known as 5-O-desmethyl-25B-NBOMe, is a serotonin receptor modulator of the phenethylamine family related to the NBOMe psychedelic 25B-NBOMe. It is the 5-O-desmethyl analogue of 25B-NBOMe. The drug is a potent agonist of the serotonin 5-HT2A and 5-HT2C receptors. Its affinity (Kᵢ), EC₅₀ (half-maximal effective concentration), and Eₘₐₓ (maximal efficacy) values at the serotonin 5-HT2A receptor were 2.24 nM, 1.20 nM, and 61%, respectively, whereas its values at the serotonin 5-HT2C receptor were 10.5 nM, 0.617 nM, and 73%, respectively. At the serotonin 5-HT2A receptor, the drug showed 11-fold lower affinity, 1.3-fold lower activational potency, and a numerical efficacy decrease of 22% compared to 25B-NBOMe. It is a major metabolite of 25B-NBOMe and is formed by cytochrome P450 enzymes. 5-DM-25B-NBOMe was first described in the scientific literature by 2016.[1–7] WP
Drug class
Serotonin receptor modulator 5-HT2A receptor agonist 5-HT2C receptor agonist WP
From the Wikipedia article's infobox.
Chemistry
Harm reduction information
No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
Sources
- Journal / agency Duan W, Cao D, Wang S, Cheng J. Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants. Chemical Reviews. January 2024. doi:10.1021/acs.chemrev.3c00375 · PMID 38033123
- Journal / agency Leth-Petersen S, Petersen IN, Jensen AA, Bundgaard C, Bæk M, Kehler J, Kristensen JL. 5-HT2A/5-HT2C Receptor Pharmacology and Intrinsic Clearance of N-Benzylphenethylamines Modified at the Primary Site of Metabolism. ACS Chemical Neuroscience. November 2016. doi:10.1021/acschemneuro.6b00265 · PMID 27564969
- Journal / agency Marcher-Rørsted E, Halberstadt AL, Klein AK, Chatha M, Jademyr S, Jensen AA, Kristensen JL. Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists. ACS Chemical Neuroscience. May 2020. doi:10.1021/acschemneuro.0c00129 · PMID 32212672
- Journal / agency Poulie CB, Jensen AA, Halberstadt AL, Kristensen JL. DARK Classics in Chemical Neuroscience: NBOMes. ACS Chemical Neuroscience. December 2020. doi:10.1021/acschemneuro.9b00528 · PMID 31657895 · PMC9191638
- Journal / agency Halberstadt AL. Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens. Current Topics in Behavioral Neurosciences. 2017. doi:10.1007/7854_2016_64 · PMID 28097528
- Journal / agency Leth-Petersen S, Gabel-Jensen C, Gillings N, Lehel S, Hansen HD, Knudsen GM, Kristensen JL. Metabolic Fate of Hallucinogenic NBOMes. Chemical Research in Toxicology. January 2016. doi:10.1021/acs.chemrestox.5b00450 · PMID 26669514
- Journal / agency Boumrah Y, Humbert L, Phanithavong M, Khimeche K, Dahmani A, Allorge D. In vitro characterization of potential CYP- and UGT-derived metabolites of the psychoactive drug 25B-NBOMe using LC-high resolution MS. Drug Testing and Analysis. February 2016. doi:10.1002/dta.1865 · PMID 26382567
Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.